(NASDAQ: CSTL) Castle Biosciences's forecast annual revenue growth rate of -4.05% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 4.82%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.9%.
Castle Biosciences's revenue in 2025 is $346,269,000.On average, 1 Wall Street analysts forecast CSTL's revenue for 2025 to be $9,238,847,416, with the lowest CSTL revenue forecast at $9,238,847,416, and the highest CSTL revenue forecast at $9,238,847,416. On average, 1 Wall Street analysts forecast CSTL's revenue for 2026 to be $8,819,677,755, with the lowest CSTL revenue forecast at $8,819,677,755, and the highest CSTL revenue forecast at $8,819,677,755.
In 2027, CSTL is forecast to generate $9,685,574,943 in revenue, with the lowest revenue forecast at $9,685,574,943 and the highest revenue forecast at $9,685,574,943.